Biogen Avonex Overtakes Berlex' Betaseron In Europe, Leads MS Market
Biogen's Avonex currently holds 57% of the U.S. multiple sclerosis market, and has recently surpassed Berlex' Betaseron to lead the European market with a 43% share, Biogen Treasurer John Conley told analysts at the Paine Webber Growth & Technology Conference in New York City June 9.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth